Skip to main content

Table 4 Efficacy of IL-2 in treating MPE

From: Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients

Study Study size (N) Study design Efficacy of therapy Improvement of QOL (N; %)
Group 1 Group 2 Group 1 Group 2 Group 1 Group 2
Group 1 Group 2 CR PR SD PD CR PR SD PD N % N %
Changjie H 2001 [15] 30 30 Cisplatin+IL-2 Cisplatin 16 10 4 6 8 16
Xiuzhi Y 2001 [16] 40 20 Cisplatin+IL-2 Cisplatin 17 19 5 8 7 5
Zhuo S 2004 [17] 32 30 Cisplatin+IL-2 Cisplatin 14 12 4 2 5 10 6 9 20 63 11 37
Junyan W 2005 [18] 48 34 Cisplatin+IL-2 Cisplatin 25 14 9 12 8 14
Haiying X 2009 [19] 35 28 Cisplatin+IL-2 Cisplatin 10 18 7 3 12 13
Xiaoxia H 2009 [20] 37 35 Cisplatin+IL-2 Cisplatin 15 16 3 3 8 11 7 9 29 78.3 19 54.3
Lizheng C 2009 [21] 46 40 Cisplatin+IL-2 Cisplatin 26 13 7 13 10 17
Jinguang C 2009 [22] 31 31 Cisplatin+IL-2 Cisplatin 12 17 2 7 13 11  
Junfeng W 2010 [23] 41 41 Cisplatin+IL-2 Cisplatin 29 4 3 5 7 15 3 16
Jingping Z 2010 [24] 63 61 Cisplatin+IL-2 Cisplatin 25 30 5 3 12 22 4 23
Cheng X 2010 [25] 41 41 Cisplatin+IL-2 Cisplatin 21 17 3 13 8 20
Fang S 2011 [26] 30 30 Cisplatin+IL-2 Cisplatin 9 17 4 7 14 9 26 86.7 24 80
Xueling L 2011 [27] 34 34 Cisplatin+IL-2 Cisplatin 19 11 4 8 10 16
Yan Q 2011 [28] 41 35 Cisplatin+IL-2 Cisplatin 12 24 3 2 6 12 4 13
Li J 2013 [29] 38 35 Cisplatin+IL-2 Cisplatin 12 13 13 4 11 20 27 71.1 17 48.6
Lijie H 2014 [30] 30 30 Cisplatin+IL-2 Cisplatin 12 13 5 7 10 13 26 86.7 19 63.3
Miao H 2016 [31] 31 30 Cisplatin+IL-2 Cisplatin 11 15 5 7 10 13
Baohua Y 2017 [32] 33 33 Cisplatin+IL-2 Cisplatin 11 18 3 1 8 14 6 5
  1. N, cases, IL-2 interleukin-2; Group 1 = IL-2 combined+cisplatin; Group 2 = cisplatin alone, CR complete response, PR partial response, SD stable disease, PD progressive disease, QOL quality of life